Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib in EGFR/HER2+ Advanced Cancers
NCT00748709Phase 2Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2008
- Primary completion
- Nov 2010
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of afatinib in gastric cancer (GC), esophageal cancer, biliary tract cancer (BTC), gallbladder cancer, urothelial carcinoma (UC), sponsored by Boehringer Ingelheim. Started Oct 2008; status: terminated.
02
Drugs
afatinib
03
Conditions
gastric cancer (GC)esophageal cancerbiliary tract cancer (BTC)gallbladder cancerurothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT00748709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00748709.